Cameron Turtle, Chief Executive Officer at Spyre Therapeutics, Inc. (SYRE), sold 15,000 shares at $93.97 ($1.4M) on 2026-08-03, disclosed to the SEC on 2026-08-05.
Scheduled sale ($1.4M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $93.97 | 800 | $75K | 5.2% |
| 2 | $95.10 | 7,157 | $681K | 47.5% |
| 3 | $95.93 | 5,635 | $541K | 37.7% |
| 4 | $96.82 | 1,392 | $135K | 9.4% |
| 5 | $97.46 | 16 | $2K | 0.1% |
| Total | $95.51 avg | 15,000 |
| $1.4M |
| 100% |
| Filing → |
| SYRE | SELL | 2026-07-02 | $1.3M | — | Filing → |
| SYRE | SELL | 2026-06-03 | $1.1M | — | Filing → |
| SYRE | SELL | 2026-05-01 | $1.1M | — | Filing → |